Supplemental material, sj-pdf-6-pmj-10.1177_02692163221142950 for Healthcare use and healthcare costs for patients with advanced cancer; the international ACTION cluster-randomised trial on advance care planning by Ida J Korfage, Suzanne Polinder, Nancy Preston, Johannes JM van Delden, A)JLM Geraerds, Lesley Dunleavy, Kristof Faes, Guido Miccinesi, Giulia Carreras, Caroline Moeller Arnfeldt, Marijke C Kars, Giuseppe Lippi, Urska Lunder, Ceu Mateus, Kristian Pollock, Luc Deliens, Mogens Groenvold, Agnes van der Heide and Judith AC Rietjens in Palliative Medicine

Additional file 2. Trial participants’ information sheet.

Additional file 4. Workwell trial: NPT constructs mapped to participants and employer topic guide.

Additional file 4. Workwell trial: NPT constructs mapped to participants and employer topic guide.

Spinal cord injury (SCI) is a serious central nervous system disease, and secondary injury, including oxidative stress, the inflammatory response and accompanying neuronal apoptosis, will aggravate the condition. Due to the existence of the blood–spinal cord barrier (BSCB), the existing drugs for SCI treatment are difficulty to reach the injury site and thus their efficacy is limited. In this study, we designed chitosan-modified hollow manganese dioxide nanoparticles (CM) for the delivery of resveratrol to help...

Additional file 1. Supplementary Figure 1: comparison with the deduced amino acid sequence of the OIE-ESP recommended vaccine strain against Florida clade2. Supplementary Figure 2: comparison with the deduced amino acid sequence of the whole inactivated EI vaccine strain available in Egypt (Egypt/6066NAMRU-VSVRI/2008). Supplementary Figure 3: Comparison of the deduced amino acid sequences of the present study with the EI vaccine (KY97) strain available in Egypt as Fluvac innovator® 4 (Zoetis-US).

Additional file 3. Trial participants’ consent form.

Additional file 5. Workwell trial: NPT constructs mapped to therapist topic guide.

Supplemental material, sj-pdf-1-pmj-10.1177_02692163221142950 for Healthcare use and healthcare costs for patients with advanced cancer; the international ACTION cluster-randomised trial on advance care planning by Ida J Korfage, Suzanne Polinder, Nancy Preston, Johannes JM van Delden, A)JLM Geraerds, Lesley Dunleavy, Kristof Faes, Guido Miccinesi, Giulia Carreras, Caroline Moeller Arnfeldt, Marijke C Kars, Giuseppe Lippi, Urska Lunder, Ceu Mateus, Kristian Pollock, Luc Deliens, Mogens Groenvold, Agnes van der Heide and Judith AC Rietjens in Palliative Medicine

Supplemental material, sj-pdf-3-pmj-10.1177_02692163221142950 for Healthcare use and healthcare costs for patients with advanced cancer; the international ACTION cluster-randomised trial on advance care planning by Ida J Korfage, Suzanne Polinder, Nancy Preston, Johannes JM van Delden, A)JLM Geraerds, Lesley Dunleavy, Kristof Faes, Guido Miccinesi, Giulia Carreras, Caroline Moeller Arnfeldt, Marijke C Kars, Giuseppe Lippi, Urska Lunder, Ceu Mateus, Kristian Pollock, Luc Deliens, Mogens Groenvold, Agnes van der Heide and Judith AC Rietjens in Palliative Medicine

Supplemental material, sj-pdf-5-pmj-10.1177_02692163221142950 for Healthcare use and healthcare costs for patients with advanced cancer; the international ACTION cluster-randomised trial on advance care planning by Ida J Korfage, Suzanne Polinder, Nancy Preston, Johannes JM van Delden, A)JLM Geraerds, Lesley Dunleavy, Kristof Faes, Guido Miccinesi, Giulia Carreras, Caroline Moeller Arnfeldt, Marijke C Kars, Giuseppe Lippi, Urska Lunder, Ceu Mateus, Kristian Pollock, Luc Deliens, Mogens Groenvold, Agnes van der Heide and Judith AC Rietjens in Palliative Medicine